Drug Updates

FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma

Drug Updates, FDA Approvals, News & Updates, In the News

On February 12, 2019, the US Food and Drug Administration (FDA) granted approval for daratumumab (Darzalex; Janssen), a CD38-directed antibody, to be given in a split-dosing regimen to patients with multiple myeloma (MM). Darzalex is the first and only CD38-directed antibody to receive regulatory approval for the treatment of patients with MM and is the first to be approved for the split-dosing regimen. This new regimen gives patients and healthcare providers the option to split the first dose of Darzalex over the course of 2 consecutive days, which has the benefit of shortening the duration of the first infusion. [ Read More ]

Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer

Lisa A. Raedler, PhD, RPh

September 2017, Vol 7, No 9 - Breast Cancer, Drug Updates

Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 252,710 American women will be diagnosed with breast cancer and 40,610 will die from the disease in 2017. For the majority (62%) of women with breast cancer, the disease is confined to the breast, and the 5-year survival approaches 100%. However, for women with metastatic disease, the likelihood of survival at 5 years drops to 27%. [ Read More ]

Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma

Lisa A. Raedler, PhD, RPh

August 2017, Vol 7, No 8 - Drug Updates

Marginal-zone lymphoma (MZL) is a malignancy that arises from B-lymphocytes in the marginal zone of lymphoid tissue. This slow-growing indolent B-cell lymphoma represents approximately 12% of all cases of non-Hodgkin lymphoma (NHL) in adults. MZL is divided into 3 subtypes, including mucosa-associated lymphoid tissue (MALT), nodal MZL, and splenic MZL. [ Read More ]

Lenvima (Lenvatinib) Approved in Combination with Everolimus for Patients with Advanced Renal-Cell Carcinoma

Loretta Fala

February 2017, Vol 7, No 2 - Drug Updates

Approximately 394,336 Amer­icans were living with kidney cancer in 2013. In 2016 alone, an estimated 62,700 people were diagnosed with kidney cancer, and 14,240 people died from the disease. Renal-cell carcinoma (RCC), the most common type of kidney cancer, accounts for 85% to 90% of new cases of the disease. More than 70% of kidney cancers are clear-cell tumors—named for the clearness (or paleness) of the cells when viewed under a microscope. [ Read More ]